Active ingredientCobimetinibCat. No. P-C234-001CAS 934660-93-2Family · Pharmaceutical analytical standards
Cobimetinib
An oral MEK kinase inhibitor, approved in the United States in 2015 for BRAF V600-mutated melanoma in combination with vemurafenib, and later also for histiocytic neoplasms in adults. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It works as part of a pair: vemurafenib blocks the BRAF protein and cobimetinib the next link, MEK, so the same signalling chain that drives tumour cells to multiply is interrupted at two points.
Go to the active ingredient →Active ingredientCobimetinibCat. No. P-C234-001CAS 934660-93-2
Isotopically labelledCobimetinib-d9Cat. No. P-C234-002
ImpurityCobimetinib Impurity 1 HydrochlorideCat. No. P-C234-003CAS 2065147-70-6
ImpurityCobimetinib Impurity 2Cat. No. P-C234-004CAS 152361-26-7No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.